ArticleJournal of experimental & clinical cancer research : CR2019

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.

Xuejiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.